Redirecting to https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-for-patients-with-msi%e2%80%91h-dmmr-advanced-endometrial-carcinoma-who-have-disease-progression-following-prior-systemic-therapy-in-any-se/...

Click here if your browser doesn't automatically take you to this page.